The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,304.00
Bid: 1,303.50
Ask: 1,304.50
Change: -22.00 (-1.66%)
Spread: 1.00 (0.077%)
Open: 1,331.00
High: 1,334.50
Low: 1,303.50
Prev. Close: 1,326.00
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of new Chief Executive Officer

24 Jun 2020 07:00

RNS Number : 8588Q
Persimmon PLC
24 June 2020
 

24 June 2020

Persimmon plc

 

Appointment of new Chief Executive Officer

 

 

The Board of Persimmon Plc is pleased to announce the appointment of Dean Finch as Group Chief Executive. Dean will succeed David Jenkinson, who announced in February 2020 that he wished to step down once a suitable successor had been identified. Dean, 53, is expected to join the Persimmon Board and take up the CEO post at the end of the year.

 

Dean is a widely experienced senior executive with a strong commercial, financial and operational track record spanning a 30-year career in Europe and North America. He has been the CEO of National Express plc since 2010, and during his tenure has built the business into Britain's leading transport group. Prior to that he was Group Chief Executive of Tube Lines and Group Finance Director and Group Chief Operating Officer at First Group plc, where he also held a number of other senior roles.

 

Roger Devlin, Persimmon's Chairman, said: "Dean is a seasoned, well-respected and proven Chief Executive with an exceptional record. In his current role he has delivered substantial strategic and operational progress over a sustained period, delivering value for all stakeholders in the business while developing a distinct and cohesive culture, focused on customer care and service. The Board believes that Dean is a great fit for Persimmon and is well qualified to lead the business into the next phase as we continue to drive a programme of change to become the leading volume builder of good value, quality family homes throughout the UK. I look forward to welcoming him to the Company at the end of the year.

 

"I would also like to thank Dave Jenkinson for his outstanding contribution to Persimmon over many years, and particularly for his decisive leadership during the Covid-19 outbreak. Dave has committed to lead the business until the conclusion of the current financial year in December."

 

Dean Finch said: "Persimmon is a strong business operating in a sector that has a critical role to play for both the people and the economy of the UK as we emerge from the profound disruption of Covid-19. I look forward to leading the business in its drive to become Britain's best housebuilder and delivering for all stakeholders in the business whilst continuing to deliver strong financial returns to investors."

 

Remuneration

All remuneration arrangements for Dean are consistent with the terms of the Directors' Remuneration Policy approved by shareholders at the AGM in April 2020. As Group Chief Executive, Dean will receive an annual base salary of £725,000 and a pension allowance of 9% of salary in line with the contribution available for Persimmon's salaried employees. From 1 January 2021 he will be able to participate in the Company's existing annual bonus plan up to a maximum of 200% of salary (with 50% of any bonus earned being deferred into Persimmon shares for three years), and the Performance Share Plan up to 200% of salary (based on performance over three years and subject to a further two year holding period). As set out in the remuneration policy for the Executive Directors, a significant proportion of Dean's remuneration will be based on non-financial metrics including customer care and quality.

 

Dean will also receive awards in Persimmon shares to compensate for some, but not all, of the remuneration he is forfeiting on leaving his previous employer. These will remain subject to performance conditions where appropriate and reflect the value of the forfeited awards. The vesting timeline of the replacement awards will be the same as (or extended from) those which apply to the forfeited awards. Details will be disclosed in Persimmon's Directors' Remuneration Report for the year ending 31 December 2020.

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Group is Tracy Davison, Company Secretary.

 

 

For further information, please contact:

Citigate Dewe Rogerson

Simon Rigby / Kevin Smith / Jos Bieneman

Tel: +44 (0)20 7638 9571

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOADBGDLCDDDGGX
Date   Source Headline
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights
1st Nov 20229:24 amRNSHolding(s) in Company
10th Oct 20222:24 pmRNSDirector/PDMR Shareholding
5th Oct 202210:26 amRNSHolding(s) in Company
4th Oct 20223:07 pmRNSDirector/PDMR Shareholding
3rd Oct 20222:12 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.